Zugazagoitia J - Search Results

1

Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.

Agulló-Ortuño MT, García-Ruiz I, Díaz-García CV, Enguita AB, Pardo-Marqués V, Prieto-García E, Ponce S, Iglesias L, Zugazagoitia J, López-Martín JA, Paz-Ares L, Nuñez JA. Agulló-Ortuño MT, et al. Among authors: zugazagoitia j. Cancer Chemother Pharmacol. 2020 Mar;85(3):525-535. doi: 10.1007/s00280-019-04008-9. Epub 2019 Dec 12. Cancer Chemother Pharmacol. 2020. PMID: 31832811

2

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.

Zugazagoitia J, Puente J, González-Larriba JL, Manzano A, Sotelo M, Hernández S, Sanz J, Pérez P, Díaz-Rubio E. Zugazagoitia J, et al. Oncology. 2013;84(5):255-64. doi: 10.1159/000346534. Epub 2013 Feb 20. Oncology. 2013. PMID: 23428780

3

The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. Zugazagoitia J, et al. J Thorac Dis. 2014 Oct;6(Suppl 5):S526-36. doi: 10.3978/j.issn.2072-1439.2014.01.27. J Thorac Dis. 2014. PMID: 25349703 Free PMC article. Review.

4

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E. Cedrés S, et al. Among authors: zugazagoitia j. PLoS One. 2015 Mar 16;10(3):e0121071. doi: 10.1371/journal.pone.0121071. eCollection 2015. PLoS One. 2015. PMID: 25774992 Free PMC article.

5

Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?

Zugazagoitia J, Ponce S, Paz-Ares L. Zugazagoitia J, et al. Transl Lung Cancer Res. 2016 Feb;5(1):95-7. doi: 10.3978/j.issn.2218-6751.2015.08.05. Transl Lung Cancer Res. 2016. PMID: 26958500 Free PMC article. No abstract available.

6

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E. Cedrés S, et al. Among authors: zugazagoitia j. Lung Cancer. 2016 Jun;96:1-6. doi: 10.1016/j.lungcan.2016.03.001. Epub 2016 Mar 10. Lung Cancer. 2016. PMID: 27133741

7

Current Challenges in Cancer Treatment.

Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Zugazagoitia J, et al. Clin Ther. 2016 Jul;38(7):1551-66. doi: 10.1016/j.clinthera.2016.03.026. Epub 2016 May 2. Clin Ther. 2016. PMID: 27158009 Review.

8

Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat.

Zugazagoitia J, Ferrer I, Paz-Ares L. Zugazagoitia J, et al. Lancet Oncol. 2016 Dec;17(12):1622-1623. doi: 10.1016/S1470-2045(16)30506-X. Epub 2016 Oct 14. Lancet Oncol. 2016. PMID: 27751845 No abstract available.

9

Biological therapies in nonsmall cell lung cancer.

Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L. Zugazagoitia J, et al. Eur Respir J. 2017 Mar 2;49(3):1601520. doi: 10.1183/13993003.01520-2016. Print 2017 Mar. Eur Respir J. 2017. PMID: 28254765 Free article. Review.

10

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.

Zugazagoitia J, Díaz A, Jimenez E, Nuñez JA, Iglesias L, Ponce-Aix S, Paz-Ares L. Zugazagoitia J, et al. Front Med (Lausanne). 2017 Apr 5;4:36. doi: 10.3389/fmed.2017.00036. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28424775 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page